Pfizer and GSK spearhead development of promising RSV vaccines

Vaccines for RSV from GSK and Pfizer to be analysed by a panel of experts with a view to informing a decision from the US FDA on their approval.
The next stage in an exciting head-to-head between Pfizer and GSK to develop the first vaccine for respiratory syncytial virus (RSV) will take place this week as a panel of experts for the US FDA come to assess the vaccines.
RSV is common cold-like respiratory virus that is responsible for the deaths of around 14,000 older adults in the US every year. A vaccine that could protect the most vulnerable from this virus would be a big step forward.
For GSK and Pfizer it would also mean securing their place in the market, with a return of up to $10 billion according to recent estimates.
The vaccine, for which approval is sought for use in adults aged 60 and over, will come under scrutiny from a panel of experts, who will then provide an independent report for the FDA to consider, eventually deciding on final approval by May of this year. If all goes to plan then the vaccine would be available for patients in time for the seasonal increase in virus prevalence in winter, providing timely protection.
Research into RSV has been ongoing since the 1960s, so to finally have a breakthrough in the development of a vaccine is a real win for the industry and a credit to the recent advances in the fields of vaccine development and infectious diseases.
"RSV is the last of the great big respiratory viruses that afflict our population on an annual basis," stated William Schaffner of Vanderbilt University Medical Centre.
Other leaders in the field, Merck, Moderna and Johnson & Johnson have also developed RSV vaccines, which are currently undergoing clinical trials.
GSK and Pfizer have been leading the charge after initial results from late-stage studies conducted by the two companies demonstrated that their vaccines prevented the occurrence of respiratory disease after infection by RSV.
The key results were as follows: GSK's vaccine was 82.6% effective in preventing lower respiratory tract disease in people of over 60 years old, and 94.1% effective in preventing severe disease in this population.
The vaccine from Pfizer was 66.7% effective in preventing lower respiratory tract disease that occurs with over two symptoms, and 85.7% effective against illness with over three symptoms.
The results are extremely promising and a favourable outcome from the panel assessment is expected with a view to approving the vaccines in the future.


Related News
-
News Trump signs executive order to cut drug prices by up to 90%
Over the weekend, President Donald Trump announced that he would be imminently signing a new executive order to cut prescription drug prices in the USA, to match those of other high-income countries.
-
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance